Footnotes
This manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.
Conflict of interest: J.D. Chalmers has received grants and personal fees from AstraZeneca, Boehringer Ingelheim, GSK, Zambon and Insmed Incorporated; a grant from Gilead; and personal fees from Novartis and Chiesi within the past 24 months.
Conflict of interest: M.L. Metersky has received consulting fees from Insmed Incorporated, Boehringer Ingelheim, California Institute for Biomedical Research and Zambon; and his institution has received clinical trial support from Insmed Incorporated.
Conflict of interest: J. Feliciano, C. Fernandez, A. Teper, A. Maes, M. Hassan and A. Chatterjee are employed by Insmed Incorporated.
This is a PDF-only article. Please click on the PDF link above to read it.
- Received December 10, 2022.
- Accepted February 14, 2023.
- Copyright ©The authors 2023
This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions{at}ersnet.org
